Wide Impact of novoGI Nitinol Compression Anastomosis at the Annual Meeting of the American Society of Colorectal Surgeons (ASCRS) 2013

ATLANTA, May 1, 2013 (GLOBE NEWSWIRE) -- novoGI Inc today announced that its nitinol-based compression anastomosis device was widely presented at the American Society of Colorectal Surgeons (ASCRS) Annual Meeting on April 28 – May 1 at the Phoenix Convention Center in Phoenix, Arizona. With more than 50 peer-reviewed publications and 10,000 procedures worldwide for the novoGI™ ColonRing, evidence demonstrates clinical results for ease of use, healing processes, and successful outcomes in regard to leak rates.

Data presented at ASCRS 2013 continue to substantiate that the novoGI™ ColonRing is especially effective in lower anterior resection (LAR) procedures with leak rates ranging from 1.9% to 4%.

Clinical presentations on compression anastomosis at ASCRS 2013 included:

  • Compression Anastomosis Is Associated With a Low Rate of Anastomotic Leakage: Intermediate Results of WCCA RETROPRESS Study. Poster presentation by WCCA Faculty members Stephen Cohen, MD, FACS, FASCRS (Atlanta Colon and Rectal Surgery, PA, Atlanta, GA), Matthew Albert, MD, FACS, FASCRS (Florida Hospital, Orlando, FL), Jose Dominguez, MD (Cox Medical Center Health, St. Louis, MO), Domingo Galliano Jr, MD, FACS, FASCRS (Fawcett Memorial Hospital, Port Charlotte, FL), and Michael Stamos, MD, FACS, FASCRS (University of California, Irvine, Irvine, CA). Abstract P318.
  • Why Is Nitinol Compression Anastomosis Important? Presentation by Abe Fingerhut, MD, DSc (hon), FACS, FRCPS (g), FRCS (Ed) (Department of Surgery, University of Athens, Hippokrateon Hospital, Athens, Greece, WCCA Training Committee Chair, WCCA Faculty) held Monday, April 29 at the novoGI booth.
  • The WCCA Compression Anastomosis Registry: What, Why, and How? Presentation by Anthony Senagore, MD, MBA, FACS (Keck School of Medicine, University of Southern California, Los Angeles, CA, WCCA Registry Committee Chair, WCCA Faculty) held Tuesday, April 30 at the novoGI booth.

On podium at ASCRS 2013, novoGI compression anastomosis technology was noted in several sessions--including The Surgeon's Toolbox Symposium and Anastomotic Techniques and Leaks Symposium --as an attractive alternative to surgical stapling.

"We are especially encouraged by the growing body of solid clinical data as well as the enthusiasm this week at ASCRS 2013 and at the recent World Congress of Compression Anastomosis (WCCA) 2nd Annual Meeting held in Phoenix last Friday," Gavriel D. Meron, president and Chief Executive Officer of novoGI commented, "Our proprietary nitinol compression anastomosis technology is the recommended device for LAR procedures. Leading colorectal surgeons are driving new clinical endeavors to enable better patient care--such as the WCCA global registry and the planning of the new COMPARE comparative, prospective, and randomized multicenter trial comparing conventional circular staplers to the novoGI™ ColonRing compression anastomosis device."

About novoGI

novoGI is focused on providing an expanding range of solutions for GI disease management through a globally branded, high quality, market driven company. The US headquarters are in Atlanta, Georgia; research, development and manufacturing facilities in Netanya, Israel; and its European headquarters are near Paris, France. The company's website is www.novoGI.com.

NOVOGI, the NOVOGI logo, the GI logo, and DEFINING THE FUTURE are trademarks and/or registered trademarks of novoGI Inc.

CONTACT: marcom@novoGI.com www.novoGI.comSource: novoGI Inc.